61636-32-6

Basic information

• Product Name: 4-BENZYL-MORPHOLIN-3-ONE
• Synonyms: 4-BENZYL-MORPHOLIN-3-ONE
• CAS NO: 61636-32-6
• Molecular Formula: C₁₁H₁₃NO₂
• Molecular Weight: 191.23
• Mol File: 61636-32-6.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 379.3°C at 760 mmHg
• Flash Point: 183.2°C
• Appearance: /
• Density: 1.17g/cm³
• Vapor Pressure: 5.92E-06mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: 2-8°C
• PKA: -0.95±0.20(Predicted)
• CAS DataBase Reference: 4-BENZYL-MORPHOLIN-3-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BENZYL-MORPHOLIN-3-ONE(61636-32-6)
• EPA Substance Registry System: 4-BENZYL-MORPHOLIN-3-ONE(61636-32-6)

Safety Data

• Hazardous Substances Data: 61636-32-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H13NO2/c13-11-9-14-7-6-12(11)8-10-4-2-1-3-5-10/h1-5H,6-9H2

Upstream product

• 104-63-2 N-Benzylethanolamine 
• 100-39-0 benzyl bromide 
• 10316-00-4 4-benzyl-morpholine 
• 2564-83-2 2,2,6,6-Tetramethyl-1-piperidinyloxy free radical 
• 349097-85-4 N-benzyl-3-chloro-N-(2-hydroxyethyl)propanamide 
• 100-44-7 benzyl chloride 
• 100129-49-5 N-benzyl-2-chloro-N-(2-hydroxyethyl)acetamide 

Downstream Products

• 1450995-69-3 (2R,3S)-4-benzyl-2-[hydroxy-(4-chlorophenyl)methyl]-morpholin-3-one 

Relevant articles and documents

5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY

The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

Transition-Metal-Free Amine Oxidation: A Chemoselective Strategy for the Late-Stage Formation of Lactams

A metal-free strategy for the formation of lactams via selective oxidation of cyclic secondary and tertiary amines is described. Molecular iodine facilitates both chemoselective and regioselective oxidation of C-H bonds directly adjacent to a cyclic amine. The mild conditions, functional group tolerance, and substrate scope are demonstrated using a suite of diverse small molecule cyclic amines, including clinically approved drug scaffolds.

ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES

The present invention relates to compounds of the formula (I) wherein R1, R2, R3, X, Y and the dashed line are defined in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use as psychotherapeutic agents.